Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $37.2 million.

  • Zentalis Pharmaceuticals' Total Current Liabilities fell 3227.04% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year decrease of 3227.04%. This contributed to the annual value of $52.7 million for FY2024, which is 2399.12% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Total Current Liabilities stood at $37.2 million for Q3 2025, which was down 3227.04% from $39.0 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Total Current Liabilities ranged from a high of $69.4 million in Q4 2023 and a low of $37.2 million during Q3 2025
  • Over the past 4 years, Zentalis Pharmaceuticals' median Total Current Liabilities value was $54.1 million (recorded in 2022), while the average stood at $52.9 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Total Current Liabilities surged by 2960.33% in 2023, and later tumbled by 4148.92% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Total Current Liabilities (Quarter) stood at $56.6 million in 2022, then rose by 22.45% to $69.4 million in 2023, then decreased by 23.99% to $52.7 million in 2024, then dropped by 29.51% to $37.2 million in 2025.
  • Its Total Current Liabilities was $37.2 million in Q3 2025, compared to $39.0 million in Q2 2025 and $49.4 million in Q1 2025.